Acyclovir vs Oseltamivir

Acyclovir is highly effective against herpesvirus family infections. For genital herpes, it reduces the duration of outbreaks by 1-2 days and decreases viral shedding. For shingles, early treatment (within 72 hours of rash onset) significantly reduces pain duration and the risk of postherpetic neuralgia. Acyclovir has been a cornerstone of antiviral therapy since its FDA approval in 1982.

Oseltamivir is effective against influenza when started within 48 hours of symptom onset, reducing illness duration by approximately 1-1.5 days. It is also FDA-approved for influenza prophylaxis in people aged 1 year and older. Clinical trials have shown that oseltamivir reduces the risk of influenza complications such as pneumonia and hospitalization, particularly in high-risk populations including the elderly and immunocompromised patients.

Direct efficacy comparison between these drugs is not clinically meaningful since they treat different infections. The choice between them depends entirely on the diagnosed viral illness.

Acyclovir is generally well tolerated. Common side effects include nausea, diarrhea, headache, and malaise. With intravenous administration, renal toxicity is a concern, and adequate hydration is essential. Rare but serious side effects include thrombotic thrombocytopenic purpura (TTP) and neurotoxicity, particularly in patients with renal impairment.

Oseltamivir commonly causes nausea and vomiting, which can be minimized by taking the medication with food. Rare neuropsychiatric events, including delirium and self-injury, have been reported primarily in pediatric patients in Japan, though a causal relationship has not been firmly established. The FDA added a precautionary warning about these events in 2006.

Both medications are considered safe when used appropriately. Acyclovir requires dose adjustment in renal impairment, while oseltamivir requires dose adjustment in patients with creatinine clearance below 60 mL/min.

Generic acyclovir is widely available and relatively inexpensive, typically costing $10-30 for a standard course of treatment. Oral acyclovir is available in 200mg, 400mg, and 800mg tablets and capsules. The cost of branded Zovirax is significantly higher.

Generic oseltamivir has become more affordable since patent expiration, but it typically costs $30-60 for a 5-day treatment course. During influenza season, demand can drive prices higher. Brand-name Tamiflu remains more expensive at $100-150 per course.

Insurance coverage for both medications is generally good, as both are included on most formularies. However, some plans may require prior authorization for oseltamivir prophylaxis use.

Acyclovir is typically taken 2-5 times daily depending on the indication, which can be inconvenient for patients. Treatment courses vary from 5-10 days for acute episodes. For suppressive therapy in recurrent genital herpes, acyclovir is taken twice daily indefinitely.

Oseltamivir is taken twice daily for 5 days for treatment, or once daily for prophylaxis. Its simpler dosing schedule and shorter treatment duration make it somewhat more convenient, though the narrow treatment window (must start within 48 hours of symptoms) adds urgency to obtaining a prescription.

The choice between acyclovir and oseltamivir is determined by the specific viral infection being treated, not by patient preference. Acyclovir is the appropriate choice for herpesvirus infections including cold sores, genital herpes, chickenpox, and shingles. Oseltamivir is the appropriate choice for influenza A and B.

If you suspect you have influenza, seek medical attention promptly, as oseltamivir is most effective when started within 48 hours of symptom onset. For herpes-related infections, early treatment with acyclovir also improves outcomes but is less time-sensitive than oseltamivir for flu.

Consult your healthcare provider for proper diagnosis and treatment selection, as accurate identification of the underlying viral infection is essential for choosing the right antiviral medication.